Reason for request
Inclusion
Clinical Benefit
| Substantial |
Substantial actual benefit |
Clinical Added Value
| important |
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation. |
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
SdfRNLFbEL4MCpWX
